Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price traded up 10.3% during mid-day trading on Wednesday . The stock traded as high as $14.28 and last traded at $14.61. 763,417 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 1,027,705 shares. The stock had previously closed at $13.24.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on the company. Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the company a "buy" rating in a research report on Friday. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a research report on Friday. LADENBURG THALM/SH SH started coverage on Urogen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of Urogen Pharma in a research report on Thursday, June 12th. Finally, HC Wainwright upgraded Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target for the company in a research note on Monday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $32.86.
View Our Latest Analysis on URGN
Urogen Pharma Trading Up 12.0%
The company has a quick ratio of 5.47, a current ratio of 5.65 and a debt-to-equity ratio of 4.77. The firm has a market cap of $684.04 million, a price-to-earnings ratio of -4.67 and a beta of 0.40. The business has a 50 day moving average price of $8.69 and a 200-day moving average price of $10.07.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. As a group, research analysts expect that Urogen Pharma will post -3.12 EPS for the current fiscal year.
Insider Activity
In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the sale, the insider now owns 153,378 shares in the company, valued at $1,130,395.86. This trade represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.10% of the company's stock.
Institutional Investors Weigh In On Urogen Pharma
A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC lifted its holdings in Urogen Pharma by 94.3% during the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock worth $566,000 after buying an additional 24,839 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after purchasing an additional 2,983,368 shares during the last quarter. Parkman Healthcare Partners LLC lifted its holdings in shares of Urogen Pharma by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock worth $4,348,000 after purchasing an additional 23,292 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after purchasing an additional 1,653 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after purchasing an additional 88,577 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
Urogen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
